Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Literature DB >> 9257770

In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

Abstract

MICs of Bay 12-8039 and comparative antimicrobials were determined for 820 recent clinical isolates. Ciprofloxacin was approximately 2-fold more active than Bay 12-8039 and ofloxacin against Enterobacteriaceae and approximately 8-fold more active against Pseudomonas aeruginosa. Bay 12-8039 was approximately 2- to 16-fold more active than ciproiloxacin and ofloxacin against nonfermenters (except P. aeruginosa), staphylococci, streptococci, enterococci, and anaerobes. As determined by regression analysis, there was a high degree of correlation among quinolone MICs.

Entities: Chemical Species

Mesh：

Substances：

Year: 1997 PMID： 9257770 PMCID： PMC164014

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

8 in total

1. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.

Authors: R J Fass; J Barnishan; M C Solomon; L W Ayers
Journal: Antimicrob Agents Chemother Date: 1996-06 Impact factor: 5.191

2. Cross-resistance and cross-susceptibility between fluoroquinolone agents.

Authors: A L Barry; P C Fuchs
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-12 Impact factor: 3.267

3. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.

Authors: A King; L Bethune; I Phillips
Journal: J Antimicrob Chemother Date: 1991-11 Impact factor: 5.790

4. In vitro activity of Bay y 3118, a new quinolone.

Authors: R J Fass
Journal: Antimicrob Agents Chemother Date: 1993-11 Impact factor: 5.191

5. In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors: J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal: Antimicrob Agents Chemother Date: 1997-01 Impact factor: 5.191

6. Use of frequency distribution curves, scattergrams and regression analyses to compare in vitro activities and describe cross-susceptibility and cross-resistance among four quinolones.

Authors: R J Fass
Journal: J Chemother Date: 1994-12 Impact factor: 1.714

7. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.

Authors: K S Thomson; C C Sanders; M E Hayden
Journal: Antimicrob Agents Chemother Date: 1991-11 Impact factor: 5.191

8. In vitro activity of ciprofloxacin (Bay o 9867).

Authors: R J Fass
Journal: Antimicrob Agents Chemother Date: 1983-10 Impact factor: 5.191

8 in total

19 in total

1. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

Authors: Jutta Wagner; Miriam Jabbusch; Martin Eisenblätter; Helmut Hahn; Constanze Wendt; Ralf Ignatius
Journal: Antimicrob Agents Chemother Date: 2003-07 Impact factor: 5.191

2. Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.

Authors: Rose Jung; Maroof Husain; Michael K Choi; Douglas N Fish
Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191

Review 9. Moxifloxacin.

Authors: J A Balfour; L R Wiseman
Journal: Drugs Date: 1999-03 Impact factor: 9.546

10. Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis.

Authors: J Barth; H Landen
Journal: Clin Drug Investig Date: 2003 Impact factor: 2.859

In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.

1. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.

2. Cross-resistance and cross-susceptibility between fluoroquinolone agents.

3. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.

4. In vitro activity of Bay y 3118, a new quinolone.

5. In vitro activity of BAY 12-8039, a new fluoroquinolone.

6. Use of frequency distribution curves, scattergrams and regression analyses to compare in vitro activities and describe cross-susceptibility and cross-resistance among four quinolones.

7. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.

8. In vitro activity of ciprofloxacin (Bay o 9867).

1. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.

2. Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.

3. Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

4. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells.

5. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

6. The new fluoroquinolones: A critical review.

Review 7. Ofloxacin otic solution: a review of its use in the management of ear infections.

Review 8. A critical review of the fluoroquinolones: focus on respiratory infections.

Review 9. Moxifloxacin.

10. Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis.